Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.83 |
| ▸ | FABP4 | P15090 | 3/20 | 0.74 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.74 |
| ▸ | FABP3 | P05413 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.61 |
| ▸ | FNTA | P49354 | 1/20 | 0.50 |
| ▸ | FNTB | P49356 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | RORA | P35398 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | RORB | Q92753 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20961263 | 0.95 | KDM4E (0.80) | KDM4EFABP4FABP5FABP3HDAC6 | |
| SCHEMBL20961100 | 0.93 | KDM4E (0.77) | KDM4EFABP4FABP5FABP3HDAC6 | |
| SCHEMBL3322057 | 0.91 | KDM4E (1.00) | KDM4EFABP4FABP5FABP3HDAC6 | |
| SCHEMBL4314440 | 0.85 | FABP4 (1.00) | KDM4EFABP4FABP5FABP3HDAC6 | |
| SCHEMBL30573159 | 0.85 | FABP4 (1.00) | KDM4EFABP4FABP5FABP3HDAC6 | |
| SCHEMBL11606635 | 0.84 | ALDH1A1 (0.68) | KDM4EFABP4FABP5FABP3HDAC6 | |
| SCHEMBL11608105 | 0.80 | KDM4E (0.55) | KDM4EFABP4FABP5FABP3HDAC6 | |
| SCHEMBL12951764 | 0.80 | FABP4 (1.00) | KDM4EFABP4FABP5FABP3HDAC6 | |
| SCHEMBL1352112 | 0.80 | FABP4 (0.71) | KDM4EFABP4FABP5FABP3HDAC6 | |
| SCHEMBL4552481 | 0.80 | FABP4 (0.68) | FABP4FABP5FABP3HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115137-B2 | 2,3,4,5-tetrahydro-1H-pyrido[4,3-B]indole compounds and methods of use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| CN-101983059-B | New 2,3,4,5-terahydro-1h-pyrido[ 4,3-b] indole compounds and methods of use thereof | MEDIVATION TECHNOLOGIES INC | 2014-11-05 | — | — | CN | disclosed |
| US-20130190348-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190347-A1 | 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| CN-101983059-A | New 2,3,4,5-terahydro-1h-pyrido[ 4,3-b] indole compounds and methods of use thereof | MEDIVATION TECHNOLOGIES INC | 2011-03-02 | — | — | CN | disclosed |
| EP-2244708-A1 | NEW 2,3,4,5-TEtRAHYDRO-1H-PYRIDO [4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF | Medivation Technologies, Inc. (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100022580-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. | 2010-01-28 | — | — | US | disclosed |
| WO-2009094668-A1 | NEW 2,3,4,5-TERAHYDRO-1H-PYRIDO[ 4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190347-A1 | 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | HTR2C, HTR3B, HTR4 | KDM4E 1661/4885FABP4 4531/4885FABP5 2444/4885 |
| US-20100022580-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | HTR2C, HTR3B, HTR4 | KDM4E 1646/4885FABP4 4597/4885FABP5 2538/4885 |
| US-20130190348-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF | HTR2C, HTR3B, HTR4 | KDM4E 1646/4885FABP4 4597/4885FABP5 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.